%0 Journal Article
%T Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper.
%A Silvestris N
%A Argentiero A
%A Cosmai L
%A Porta C
%A Gesualdo L
%A Brunori G
%A Brunetti O
%A Rampino T
%A Secondino S
%A Rizzo G
%A Pedrazzoli P
%J Crit Rev Oncol Hematol
%V 140
%N 0
%D Aug 2019
%M 31176271
%F 6.625
%R 10.1016/j.critrevonc.2019.05.016
%X The increasing availability of novel biological anticancer agents has greatly improved the outcome of several cancer patients; unfortunately, data regarding efficacy, safety and pharmacokinetics of many of these agents in patients with chronic renal disease or on hemodialysis are scanty. Furthermore these results are controversial and a treatment strategy has not yet been established. Therefore, the Associazione Italiana di Oncologia Medica and the Società italiana di Nefrologia undertook the present work aiming at providing health professionals with a tool for easier clinical management of target therapies in this setting of patients. A web-based search of MEDLINE/PubMed library data published from 2000 to June 2018 has been performed. More than one hundred papers, including recommendations and expert opinions, were selected and discussed by the authors. A panel of experts provided additional biological and clinical information, helping in clarifying some issues in the absence of clear-cut information from the literature.